期刊
DIABETES
卷 62, 期 4, 页码 1131-1138出版社
AMER DIABETES ASSOC
DOI: 10.2337/db12-0797
关键词
-
资金
- NIHR Senior Investigator award
- MRC
- Wellcome Trust Clinical Research Training fellowships
- BBSRC Diet and Health Research Industry Club grant
- National Health
- Imperial College Healthcare Charity [7006/R50U]
- Medical Research Council (MRC)
- Biotechnology and Biological Sciences Research Council (BBSRC)
- National Institute for Health Research (NIHR)
- Integrative Mammalian Biology Capacity Building award
- EuroCHIP grant [FP7-HEALTH-2009-241592]
- NIHR Imperial Biomedical Research Centre within the Academic Health Sciences Centre
- NUM Senior Investigator Award
- MRC Clinical Research Training fellowships
- MRC overseas-based Clinical Research fellowship
- Medical Research Council [G0701371] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10112] Funding Source: researchfish
- MRC [G0701371] Funding Source: UKRI
Glucagon and glucagon-like peptide (GLP)-1 are the primary products of proglucagon processing from the pancreas and gut, respectively. Giving dual agonists with glucagon and GLP-1 activity to diabetic, obese mice causes enhanced weight loss and improves glucose tolerance by reduction of food intake and by increase in energy expenditure (EE). We aimed to observe the effect of a combination of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers. In a randomized, double-blinded crossover study, 10 overweight or obese volunteers without diabetes received placebo infusion, GLP-1 alone, glucagon alone, and GLP-1 plus glucagon simultaneously. Resting EE-measured using indirect calorimetry-was not affected by GLP-1 infusion but rose significantly with glucagon alone and to a similar degree with glucagon and GLP-1 together. Glucagon infusion was accompanied by a rise in plasma glucose levels, but addition of GLP-1 to glucagon rapidly reduced this excursion, due to a synergistic insulinotropic effect. The data indicate that drugs with glucagon and GLP-1 agonist activity may represent a useful treatment for type 2 diabetes and obesity. Long-term studies are required to demonstrate that this combination will reduce weight and improve glycemia in patients. Diabetes 62:1131-1138, 2013
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据